Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
VYNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.28 - $4.30
Previous CloseN/A
Volume117.27K
Average Volume (3M)178.48K
Market Cap
$21.75M
Enterprise Value$81.28M
Total Cash (Recent Filing)$78.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 08, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding15,209,862
10 Day Avg. Volume106,348
30 Day Avg. Volume178,484
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)50.21
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap3.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit162.24
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$5.88Price Target Upside311.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
VYNE Therapeutics News
See All VYNE News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityVYNE Therapeutics finished the period with $61.5M in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026.
Product AdvantagesRepibresib is administered once-daily and is not expected to have a black-box warning, which are meaningful advantages over the current standard.
Product DevelopmentRepibresib has demonstrated a well-defined mechanism of action and potential in vitiligo in previous trials, showing a strong chance of success in subsequent clinical investigations.
Bears Say
Animal Study ConcernsA clinical hold was placed on VYN202 Phase 1b trial due to recent observations of testicular toxicity in dogs from a non-clinical toxicology study.
Clinical Trial SuspensionThe Company has suspended all screening, enrollment, and dosing in the study, and is working with the FDA to resolve the hold as soon as possible.
Regulatory ChallengesFDA has placed a clinical hold on its Phase Ib study evaluating VYN202 in patients with moderate-to-severe plaque psoriasis following a recent observation of testicular toxicity in dogs.
---
Ownership Overview
11.01% Insiders
5.85% Mutual Funds
30.89% Other Institutional Investors
48.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $1.28 and its highest was $4.30 in the past 12 months.
What is VYNE Therapeutics’s market cap?
VYNE Therapeutics’s market cap is $21.75M.
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on Mar 06, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.303 by $0.023.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 15,209,862 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.303. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Currently, no hedge funds are holding shares in VYNE
---
VYNE Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.88 (311.19% Upside)
$5.88 (311.19% Upside)
Insider Transactions
Bought Shares
Worth $43.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.10%
12-Months-Change
Fundamentals
Return on Equity
-56.54%
Trailing 12-Months
Asset Growth
-31.51%
Trailing 12-Months
Company Description
VYNE Therapeutics
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
---
VYNE Stock 12 Month Forecast
Average Price Target
$5.88
▲(311.19% Upside)
Technical Analysis
Best Analysts Covering VYNE
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-12.72%
reiterated a buy rating 3 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -12.72% per trade.
---